Core Insights - Quimbaya Gold Inc. has confirmed the discovery of two new mineralized vein systems at its Tahami South Project in Colombia, indicating a significant mineralized system in a productive gold district [1][3][7] Exploration Results - The ongoing drill program at Tahami South has intersected mineralization in 8 out of 9 drill holes, demonstrating strong structural continuity and targeting accuracy [5][8] - The identified vein systems include Vein S and Vein V, which are consistent with regional quartz vein systems [2][7] - The mineralization consists of quartz, barite, carbonate veining, and a sulphide assemblage including pyrite, chalcopyrite, galena, and sphalerite [5] Strategic Implications - The discovery validates Quimbaya's exploration thesis that district-scale mineralized structures extend beyond known mines into underexplored areas [7][8] - The company has extended its drilling program beyond the initial scope due to encouraging early results, with over 4,000 meters drilled to date [5][8] Financial Position - In the second half of 2025, Quimbaya issued 2,169,164 common shares through the exercise of stock options and warrants, raising gross proceeds of C$874,665, which strengthens the company's treasury for a fully funded 2026 drill campaign [18] - The company has also granted 614,034 Restricted Share Units (RSUs) to senior management and board members to align long-term performance with shareholder value [19]

Core Insights - New Found Gold Corp. has confirmed high-grade gold mineralization at the Keats zone of its Queensway Gold Project, with notable drill results including 219 g/t Au over 9.35 m and 160 g/t Au over 10.30 m [1][5][10] Company Overview - New Found Gold Corp. holds a 100% interest in the Queensway Gold Project and is focused on advancing it into production [38] - The company has also acquired the Hammerdown Gold Project and is working towards steady-state gold production [38] Drilling Program Details - The initial results reported are from 16 of 84 diamond drill holes, representing approximately 20% of the total results from the grade control drilling program [4][6] - The drilling program aims to enhance confidence in the grade distribution of high-grade, near-surface mineralization and support mine planning [4][10] Drill Results Highlights - Significant drill results include: - 219 g/t Au over 9.35 m from 19.00 m [5] - 160 g/t Au over 10.30 m from 5.10 m [5] - 105 g/t Au over 10.20 m from 15.80 m [5] - The results align well with the initial mineral resource estimate block model, confirming strong continuity of high-grade mineralization at Keats [10] Future Plans - The company plans to expand the grade control drilling program in 2026, optimizing drill hole spacing and program scope based on 2025 results [12] - The 2025 Queensway drill program, which commenced in May 2025, is over 90% complete and is expected to finish all proposed drilling in Q4/25 [14][15] Exploration and Excavation Activities - Ongoing exploration drilling is taking place in the vicinity of the Dropkick zone, where a new zone of gold mineralization is being outlined [16] - An excavation program has been completed to validate the geological model and collect analytical information across key zones for the Preliminary Economic Assessment Phase 1 mine plan [17]

Core Insights - Tsodilo Resources Limited is continuing its collaboration with Botswana International University of Science and Technology (BIUST) to advance the Xaudum Iron Project (XIF) [1][24] - The collaboration aims to explore the high-value utilization of Botswana's natural resources, particularly iron ore, limestone, dolomite, and coal [2][5] Project Overview - The Xaudum Iron Project has defined a CIM compliant Inferred Mineral Resource Estimate of 441 million tonnes (Mt) with an average grade of 29.4% Fe [15] - An extrapolated exploration target suggests the potential for 5 to 7 billion tonnes at 15-40% Fe [15] - The project is strategically located near transport infrastructure, including the planned Trans-Zambezi Railway [16] Research and Development - BIUST received a research grant to investigate the use of a novel metallurgical coke blend in pig iron production using local resources [2][3] - Tsodilo provided BIUST with 18 meters of iron ore for testing, which has an average Fe magnetite content of 45% [4] - The project will focus on optimizing product quality through systematic changes in operational parameters [4] Environmental and Market Context - The steel industry is undergoing a shift towards lower carbon emissions, with steel production contributing approximately 11% of global CO2 emissions [7][9] - High-grade magnetite products from the XIF project are expected to be in demand due to their lower greenhouse gas emissions compared to standard iron ores [11][12] - The collaboration aims to produce pig iron, which can be further processed into steel, addressing the growing market for low-emission steel production [6][10] Economic Implications - The project is expected to enhance Botswana's export value and reduce its import bill by utilizing local resources [5] - The development of the XIF project could significantly impact Botswana's economy by diversifying it away from diamond revenue [17]

Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - The following is a list of Upcoming Meeting Dates for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service of CDS Clearing and Depository Services Inc.Company NameRecord DateMeeting DateType ANGKOR RESOURCES CORP December 19, 2025January 29, 2025AS  Aether Global Innovations CorpDecember 18, 2025February 5, 2025A  Agility Capital Holding Inc. December 15, 2025January 23, 2025AGS AnalytixInsight Inc. December 22, 2 ...

Core Viewpoint - Rosen Law Firm is urging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from November 4, 2024, to October 3, 2025 [2][6]. Group 1 - Investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 16, 2026 [4]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [5]. Group 2 - The lawsuit claims that Skye Bioscience made materially false and misleading statements regarding its product nimacimab, including its effectiveness and commercial prospects, which led to investor damages when the truth was revealed [6]. - The firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements achieved [5].

Core Points - Thermal Energy International Inc. has granted 3,334,000 stock options to its officers and directors as part of a remuneration and incentive program [1][2] - The stock options have a 5-year term and are exercisable at a price of $0.125, with specific vesting schedules for different portions of the options [2] Company Overview - Thermal Energy International Inc. specializes in energy efficiency and emissions reduction solutions, primarily serving Fortune 500 and large multinational companies [4] - The company claims to recover up to 80% of energy lost in typical boiler plant and steam system operations, providing significant financial and environmental benefits [4][5] - Thermal Energy operates as a fully accredited professional engineering firm with offices in Canada, the USA, and the UK, and has sales offices across Europe [5] Stock Information - The company's common shares are traded on the TSX Venture Exchange under the symbol TMG and on the OTCQB under the symbol TMGEF [6]

Core Viewpoint - Rosen Law Firm is reminding investors of DexCom, Inc. about an important deadline related to a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [2][4]. Group 1: Class Action Details - The class action pertains to investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, inclusive [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025 [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the devices [6]. - The allegations suggest that these actions exposed DexCom to increased regulatory scrutiny and potential legal and financial repercussions [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions of dollars for investors [5]. - In 2019, the firm secured over $438 million for investors, highlighting its effectiveness in representing clients [5].

Core Viewpoint - Rosen Law Firm is urging investors of Cepton, Inc. to secure legal counsel before the December 8, 2025 deadline related to a securities class action lawsuit concerning misleading statements made by the company during the class period from July 29, 2024, to January 6, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased or sold Cepton common stock during the specified class period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 8, 2025, and can do so by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Cepton - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations, particularly concerning a third-party bid that valued Cepton at more than double the Koito Acquisition [5]. - It is claimed that Cepton's Board of Directors failed to adequately explore this offer and did not disclose its terms, depriving shareholders of the opportunity to make an informed decision regarding the Koito Acquisition [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes its experience and success in handling securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Insights - Yaman Altal Medical Center is expanding its clinical and educational operations to enhance men's health services across the Middle East, Europe, and North Africa, reflecting a commitment to evidence-based diagnostics and public health education [1][11] Clinical Capacity and Diagnostic Services - The Center has increased its diagnostic infrastructure to support comprehensive men's health evaluations, focusing on hormonal, metabolic, urological, and preventive health indicators [5][6] - Enhancements aim to streamline patient assessment, improve clinical accuracy, and facilitate coordinated care for cross-border referrals [6] Professional Medical Training - The Center has expanded its professional training division, offering more spaces for physicians in educational and observational programs focused on diagnostic techniques and preventive care strategies [7][8] Digital Health Education Platform - The digital health education platform has surpassed 6 million verified followers, making it one of the largest online networks for evidence-based wellness education in the region [9][10] - The platform produces educational content aligned with international medical guidelines, covering topics such as hormonal balance, metabolic health, and preventive lifestyle strategies [10]

Core Insights - Zuellig Pharma has launched a new Clinical Trial Support Innovation Center in South Korea, which is positioned to be the most advanced automated hub for clinical logistics in the country, enhancing its role in global clinical research [1][2] Company Overview - Zuellig Pharma is a leading healthcare solutions provider in Asia, with a mission to improve healthcare accessibility across the region. The company has a century-long history and operates in 18 markets, employing over 12,000 staff and serving more than 200,000 medical facilities [11] Facility Details - The new facility spans 3,800 square meters and is strategically located near the Gyeongbu Expressway in Gyeonggi-do province. It aims to set new standards in clinical trial logistics through automation, digitalization, and compliance with Good Practice (GxP) [3][4] - Equipped with advanced capabilities, the facility features a fully automated order fulfillment system, enhancing the speed, accuracy, and reliability of clinical supply delivery [5] - The center supports comprehensive temperature-zone management for thousands of unique clinical trial SKUs, ensuring precise handling of temperature-sensitive products throughout the supply chain [6] Operational Impact - The facility's specialized repackaging infrastructure is designed to meet stringent clinical and regulatory standards, ensuring product integrity during the clinical trial lifecycle. It includes an integrated tracking and monitoring system for full chain-of-custody and compliance [7] - Over the past year, the center has supported more than 3,000 studies in collaboration with over 100 clients, managing approximately 13,000 outbound shipments annually, including various therapeutic products [9] Market Position - As of 2025, South Korea ranks among the top 10 clinical trial markets globally and has the third-largest number of R&D pipelines. The new facility is built to meet the rising demand for clinical trial support, aiming to improve patient access and outcomes worldwide [8]